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only 2 or less. Air leakage and bleeding from the stump didn’t occur in 
any of the patients. 
Conclusion: The reduction in the number of staplers used for VATS 
partial lung resection by DHR thus helped in improving the cost-ef-
fectiveness of the procedure. Further, the use of DHR didn’t cause any 
complications that arise due to the error of staplers. 
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Background: Cryoablation is one of the minimally invasive ablation 
modalities. We have performed percutaneous CT guided cryoablation 
under local anesthesia for local control of lung tumors. So far, in a little 
over 100 patients, we have had no major complications. In the present 
study, we report our preliminary experience in 2 cases of lung cancer 
found in the contralateral lung in postpneumonectomy patients. 
Case 1: 63 year old male. He had undergone right pneumonectomy for 
lung cancer 2 years previously. He was referred to us for metachronous 
primary lung cancer in the left upper lobe, cT1N0M0. Cryoablation 
was performed using two 2-mm probes, with adequate ablation mar-
gins. A small pneumothorax occurred after the procedure. Although the 
patient was symptom free, chest tube was inserted prophylactically. He 
was discharged 7 days post ablation.
Case 2: 59 year old female. She had undergone left pneumonectomy 
followed by chemotherapy for lung cancer 2 years previously. She was 
referred to us for suspected lung cancer metastasis in the right lower 
lobe. Cryoablation was performed using two 2-mm probes, with ad-
equate ablation margins. She was discharged 7 days post ablation.
Comments: Although the post-ablation observation period is still too 
short to evaluate local control, the cryoablation procedure was well 
tolerated in both patients. Cryoablation could become a less invasive 
alternative to partial resection under general anesthesia in postpnuemo-
nectomy patients for both metachronous primary lung cancer, and lung 
metastasis.
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Background: Non-platinum based doublets are effective treatments for 
advanced NSCLC. We performed a multicenter phase III trial to com-
pare the efﬁcacy and tolerance of oVG and DG in NSCLC patients (pts). 
Methods: Chemotherapy-naive pts with stage IIIB/IV NSCLC and PS 
(WHO) 0-2 and adequate organ function were eligible. Pts received oV 
70mg/m2 combined with G 900mg/m2 on days 1, 15 of a 4-week cycle 
or D 75mg/m2 on day 1 combined with G 1000mg/m2 on days 1, 8 of a 
3-week cycle. Primary endpoint was OS and secondary endpoints were 
response rate (RR), time to progression (TTP) and toxicity. Stratiﬁca-
tion was done for age, stage and PS. 
Results: 254 pts received oVG (n=121) or DG (n=133). Median age 
was 64 and 63 years, and PS was 0-1 in 94.2% and 94%, for oVG and 
DG, respectively. Most patients had disease stage IV and were ≤70 
years (80.9% vs 74.4% and 74% vs 77%, in oVG and DG, respective-
ly). After a median follow-up time of 6.1 months, median OS was 9.0 
vs 10.7 months and 1-yr survival was 38% vs 46% for oVG and DG, 
respectively (p=0.486). Signiﬁcantly more responders were observed 
in the DG arm (11% vs 23%, p=0.018). Median TTP was 3.1 vs 3.9 for 
oVG and DG, respectively (p=0.335). A similar toxicity proﬁle was 
observed except for a trend for higher neutropenia grade 3-4 in DG 
compared to oVG (p= 0.066). There was no difference with respect to 
neutropenic infections (p= 0.124). An analysis of the inﬂuence of age 
(≤70 and ≥ 70) on OS and toxicity revealed that OS was similar for 
both arms in the two age groups but grade 3-4 neutropenia was lower in 
the oVG arm for pts ≥70 years. 
Conclusions: A higher RR that was not translated to a survival beneﬁt 
was recorded for the DG arm. Both regimens were well tolerated with-
out signiﬁcant differences in toxicity. 
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Background: Concurrent chemoradiation (CCRT) is recommended as 
the evidence-based approach for the management of patients with stage 
IIIB non-small cell lung cancer (NSCLC) comprising 45% of initial 
